Figure 2.
Photographic evidence of tumor response in two patients. (a) Patient ID #02-033 (male metastatic breast cancer). Top panel shows primary cutaneous tumor on the breast prior to treatment. The image in the middle panel, obtained half-way through the first cycle of treatment, shows the beginning of tumor response. The bottom panel shows the dramatic change evident in the primary tumor at the end of the second round of treatment. (b) Patient ID #02-024 (angiosarcoma of the scalp). This patient received only two infusions of SGT-53 (2.4 mg DNA/ dose) and one infusion of docetaxel (75 mg/m2) before going off study. The arrows indicate areas of significant change (shrinkage and drying) of the tumor after going off study. Moreover, although not evaluable by RECIST after going off study due to a dose-limiting toxicity as described above, there is photographic evidence of tumor response in patient ID #02-024. This individual was diagnosed with angiosarcoma of the scalp which was not considered as targetable tumor by RECIST and metastatic disease to the lymph nodes. This patient received only two infusions of SGT-53 (2.4 mg DNA/dose) and one infusion of 75 mg/m2 of docetaxel before going off study. A representative image of the effect of the combination of SGT-53 and docetaxel on the angiosarcoma lesions in this patient is shown in b. As shown in this photograph, the tumor has begun to respond and reduce in size.